Woman in laboratory


Using personalised medicine to detect and treat pancreatitis and pancreatic cancer

The European Registry of Hereditary Pancreatitis and Familial Pancreatic Cancer (EUROPAC) is an internationally-renowned academic, collaborative study involving pancreas specialists from the University of Liverpool and across Europe in addressing global health issues of pancreatic diseases, which present some of the most critical of unmet clinical needs.

Pancreatic cancer alone accounts for over 400,000 deaths each year worldwide and it is predicted to become the second-highest cause of cancer death in the US by 2022. There are more than 30,000 cases of acute pancreatitis recorded each year in the UK alone, causing more than 2,000 deaths.

Chronic pancreatitis is less common and less often fatal but is extremely debilitating and affects approximately 10 out of every 100,000 people in the UK. These numbers are impressive and depressing but are dwarfed by the more than 3,000,000 UK citizens with diabetes mellitus.

EUROPAC offers hope of improved treatment and detection for all these diseases, they maintain a registry of families with a history of pancreatic conditions and offer screening to at risk individuals.

How you can help

The EUROPAC team are constantly working to improve the methods by which they carry out cancer screening, in the hope that one day it will advance to the point where potentially lifesaving screens can be offered to a wider range of people. We are also looking at data such as environmental and lifestyle factors which may influence pancreatic cancer development. Donations to the EUROPAC fund would allow them to continue and accelerate this work.

Make a gift to the EUROPAC fund today. 

If you would like to find out more about the EUROPAC trial or to possibly take part, please visit their website.

Back to: Giving